8-K current report · filed Nov 5, 2026

BioAge Labs, Inc. (BIOA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1BIOA overview

Short answer

BioAge Labs, Inc. (BIOA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.

BioAge Labs, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release attached as Exhibit 99.1, providing the substantive financial details

Item EX-99.1 · Exhibit EX-99.1

  • QUELL-CV fully enrolled at approximately 160 participants, with 30 mg, 60 mg, and 90 mg doses; topline data expected Q4 2026
  • QUELL-DME Phase 2 dosed its first participant, targeting approximately 180 patients; topline results expected in H2 2027
  • APJ obesity program remains on track for first IND submission by year-end 2026, adding a second clinical development catalyst
  • Q3 net loss widened to $33.5M, or $0.73 per share, from $20.2M, or $0.56 per share
  • Cash, equivalents, and marketable securities totaled approximately $352.3M, supporting operations and capital expenses through 2029 under the current plan

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BioAge Labs, Inc. 8-K filings

Get the next BIOA 8-K as it lands

Follow BIOA for push alerts, or ask the research agent what this filing means.